Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3
Danese D, Goss D, Romano (DeMuro) C, Gupta C. Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study. BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
Korsnes JS, Goodwin BB, Murray M, Candrilli SD. Antiretroviral treatment switching and its association with economic outcomes and adverse treatment effects among commercially insured and Medicaid-enrolled patients with HIV in the United States. Ann Pharmacother. 2016 Dec;50(12):989-1000.
Amend KL, Landon J, Thyagarajan (Hoffman) V, Niemcryk S, McAfee A. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population. Ann Pharmacother. 2011 Oct;45(10):1230-9. doi: 10.1345/aph.1Q110
Nau DP, Steinke DT, Williams LK, Austin R, Lafata JE, Divine G, Pladevall-Vila M. Adherence analysis using visual analog scale versus claims-based estimation. Ann Pharmacother. 2007 Nov;41(11):1792-7.
Williams VSL, Jones LV, Tukey JW. Controlling error in multiple comparisons, with examples from state-to-state differences in educational achievement. J Educ Behav Stat. 1999;24(1):42-69. doi: 10.3102/10769986024001042
Anthony M, Clarkson TB. Association between plasma isoflavone and plasma lipoprotein concentrations. J. Med. Food. 1999;2(3-4):263-6.